Mary T. Szela's most recent trade in Absci Corp was a trade of 178,400 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Absci Corp | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2025 | 178,400 | 178,400 | - | - | Stock Option (right to buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 28,500 | 28,500 | - | - | Option to purchase common stock | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 21,089 | 465,348 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.03 per share. | 29 Jan 2025 | 5,030 | 439,249 | - | 5.0 | 25,301 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.28 per share. | 29 Jan 2025 | 5,010 | 444,259 | - | 5.3 | 26,453 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 240,000 | 240,000 | - | - | Employee Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 40,000 | 424,677 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 27 Jan 2025 | 4,826 | 429,503 | - | 5.4 | 26,157 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.12 per share. | 27 Jan 2025 | 4,716 | 434,219 | - | 5.1 | 24,146 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 12 Sep 2024 | 7,520 | 377,382 | - | 5.2 | 39,104 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 12 Sep 2024 | 6,000 | 384,677 | - | 5 | 30,000 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 4.83 per share. | 12 Sep 2024 | 1,295 | 378,677 | - | 4.8 | 6,255 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 4.97 per share. | 10 Sep 2024 | 5,000 | 369,862 | - | 5.0 | 24,850 | Common Stock |
| Omega Therapeutics Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| TriSalus Life Sciences Inc | Szela Mary T. | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 288,750 | 288,750 | - | - | Employee Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Mary Szela T. | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 84,899 | 364,862 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 172,500 | 172,500 | - | - | Employee Stock Option (right to buy) | |
| Omega Therapeutics Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| Omega Therapeutics Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| Coherus Biosciences Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |